• Menu
  • Skip to right header navigation
  • Skip to primary navigation
  • Skip to content

DesignCaffeine, Inc.

Design That Works.

  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy

Pharmaceutical

US Patent #6677343: Substituted Piperazine Compounds

Jan 20th, 2010 //  by Greg Nudelman

Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.

Category: InventionsTag: Biochemistry, Medicinal Chemistry, Patent, Pharmaceutical

US Patent #6180615: Propargyl Phenyl Ether A2A Receptor Agonists

Jan 20th, 2010 //  by Greg Nudelman

Key CV Therapeutics/Gilead patent for A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Category: InventionsTag: Biochemistry, Medicinal Chemistry, Patent, Pharmaceutical

US Patent #6677336: Substituted Piperazine Compounds

Jan 20th, 2010 //  by Greg Nudelman

Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.

Category: InventionsTag: Biochemistry, Medicinal Chemistry, Patent, Pharmaceutical

Copyright © 2023 DesignCaffeine, Inc. · All Rights Reserved · Powered by Mai Theme